HSC Engineering for Immune and Genetic Medicine
By reprogramming the cells that build the blood and immune system, Hemavive aims to create durable, long-lasting therapies across inherited disease, autoimmunity, and transplant tolerance.
The Challenge
Personalized ex vivo cell engineering is costly, slow, and difficult to scale.
Existing vectors lack the cell-type selectivity needed to reach stem cells efficiently.
Standard conditioning regimens carry significant toxicity and restrict eligibility.
Transplant recipients face chronic immunosuppression and ongoing rejection risk.
Approved HSC gene therapies validate the field, but current approaches remain complex, costly, and difficult to scale. Hemavive is building technologies designed to simplify HSC engineering and expand access to durable therapies.
The Platform
Three complementary capabilities — engineering, delivery, and scalable manufacturing — that compound across every therapeutic program.
Precision engineering of autologous HSCs for genetic disease correction and immune reprogramming.
Delivery approaches designed to improve selectivity for hematopoietic and immune cell populations.
A closed-loop engineering concept intended to simplify, standardize, and scale selected cell engineering workflows.
Hemavive is developing a future closed-loop extracorporeal engineering concept designed to bring controlled cell engineering closer to the patient — with the goal of reducing manufacturing complexity, improving standardization, and supporting scalable therapeutic workflows.
A closed, extracorporeal approach to engineer hematopoietic and immune cells.
Therapeutic Focus
A single HSC engineering foundation, applied across genetic, autoimmune, and transplant disease.
Approved HSC gene therapies have validated the concept — but remain expensive, complex to manufacture, and dependent on toxic conditioning.
Hemavive is developing HSC engineering strategies intended to support durable correction of inherited blood and immune disorders through precise modification of hematopoietic stem cells.
Sickle cell disease, β-thalassemia, primary immunodeficiencies, and metabolic & lysosomal storage disorders.
Autoimmune diseases affect hundreds of millions globally and often require chronic immunosuppression or intensive, high-risk immune reset.
Hemavive is developing HSC-based immune reprogramming approaches designed to promote durable immune regulation by generating tolerogenic immune cell populations from engineered autologous HSCs.
Multiple sclerosis, inflammatory bowel disease, and systemic sclerosis (scleroderma).
Organ and cell transplantation still depends on lifelong immunosuppression — no scalable strategy currently induces donor-specific tolerance.
Hemavive is developing HSC-based approaches intended to promote donor-specific immune tolerance and reduce the need for chronic immunosuppression after transplantation.
Kidney, stem-cell-derived islet, liver, and heart transplantation.
The Science
Hematopoietic stem cells give rise to the entire blood and immune system. By engineering HSCs, Hemavive aims to create long-lived therapeutic programs that persist through normal hematopoiesis — so a single treatment can keep working for years.
Pipeline
Early-stage programs spanning genetic, autoimmune, and transplant indications, supported by platform and delivery development.
| Program | Initial Indication | Strategy | Stage |
|---|---|---|---|
| HSC Gene Therapy | Hemoglobinopathies / inherited blood disorders | Precision HSC engineering | Discovery / Preclinical |
| Transplant Tolerance | Type 1 diabetes / islet transplantation | Donor-specific immune tolerance | Grant-supported preclinical |
| Immune Reprogramming | MS / IBD / autoimmune disease | HSC-based immune reprogramming | Discovery |
Market Opportunity
Hemavive's platform sits at the intersection of gene therapy, autoimmune treatment, cell-therapy manufacturing, transplantation, and precision delivery — markets that compound as the science matures.
Illustrative estimate based on public industry reports; not a revenue projection. Hemavive's platform addresses a convergent opportunity across these sectors — actual opportunity is subject to regulatory outcomes and clinical validation.
Differentiation
A single HSC engineering foundation designed to address the limitations that constrain today's approaches.
| Current approaches | Limitations | Hemavive differentiation |
|---|---|---|
| Approved HSC gene therapies e.g. Casgevy, Lyfgenia |
Cost >$2M/patient; toxic conditioning; limited eligibility; no tolerance strategy | Targeted delivery + scalable engineering roadmap + tolerance programs |
| Chronic biologics e.g. anti-IL-17, anti-TNF |
Lifelong dosing; do not address root immune dysregulation | Designed for durable immune reset from a single HSC intervention |
| Autologous HSCT for autoimmunity |
High morbidity; toxic conditioning; lack of disease-specific engineering | Engineered HSC approach with lineage-directed immune reprogramming |
| Islet replacement / encapsulation | Immune rejection; encapsulation remains a barrier to scale | Donor-specific immune education to protect grafts without systemic immunosuppression |
| Immune-evasive graft engineering | Partial immune evasion; does not establish true donor-specific tolerance | Recipient-side HSC engineering for durable donor-specific tolerance |
Why Now
Four shifts in the science are converging at once — making this the moment to build on a shared HSC foundation.
HSC gene therapy is no longer experimental — approved products confirm the biology. The next challenge is scalability and cost.
Stem-cell-derived islets and tissues are moving toward clinical use — but immune rejection remains the unsolved bottleneck.
Decades of mixed-chimerism research show durable tolerance is possible. Hemavive engineers it at the molecular level — without bone marrow transplant.
A single HSC engineering platform can address genetic disease, autoimmunity, and transplant tolerance — on one scientific foundation with shared enabling technologies.
Team
A founding physician-scientist with deep HSC engineering and immune-tolerance expertise, building a scientific, clinical, strategic, and engineering advisory network.
Immunologist and translational cell-therapy scientist with experience in HSC engineering, immune tolerance, regulatory T cells, transplantation, and humanized mouse models across academic and industry settings.
Strategic, Legal & Operations
Advisory Network
Hemavive is building a scientific, clinical, strategic, and engineering advisory network to support platform development and translational strategy. Scientific, clinical, strategic, and engineering advisors are in formation.
Hemavive is seeking scientific collaborators, strategic partners, grant partners, investors, and engineering collaborators to advance its HSC engineering and delivery platforms.
Detailed technical materials are available under CDA / NDA. Contact Admin@Hemavive.com.